Literature DB >> 9534107

Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.

H H Parving1.   

Abstract

PREVALENCE: The prevalence of abnormally elevated urinary albumin excretion rate (> 30 mg/24 h) is approximately 40% in insulin-dependent and in non-insulin-dependent diabetic patients. Diabetes has become the leading cause of end-stage renal failure in Europe, USA and Japan. Approximately 90% of the direct and indirect costs of caring for diabetic patients are spent on the complications of diabetes. RISK FACTORS: Identification of patients at high risk of developing diabetic nephropathy is possible by screening for microalbuminuria (30-300 mg/24 h). Additional risk factors/ markers for development of nephropathy are male sex, genetic predisposition, ethnic conditions, early onset of diabetes, poor metabolic control, hyperfiltration, elevated prorenin and smoking. Elevated urinary albumin excretion rate indicates a substantially increased cardiovascular morbidity and mortality risk in diabetic patients. PREVENTION OF NEPHROPATHY: Randomized controlled trials in normotensive insulin-dependent and in non-insulin-dependent diabetic patients with persistent microalbuminuria indicate that angiotensin converting enzyme (ACE) inhibitors diminish urinary albumin excretion rate, and postpone and may even prevent progression to clinical overt nephropathy. These findings indicate that screening and intervention programs could probably save lives and lead to considerable economic savings. TREATMENT OF NEPHROPATHY: Systemic blood pressure elevation to a hypertensive level is an early and frequent phenomenon in diabetic nephropathy. Furthermore, nocturnal blood pressure elevation (non-dippers) occurs more frequently in patients with nephropathy. Systemic blood pressure elevation, hyperglycaemia, albuminuria and the D polymorphism in the ACE gene accelerate the progression of diabetic nephropathy. Studies of the impact of other potential progression promoters (i.e. smoking, hyperlipidaemia and protein intake) have yielded conflicting results. Effective blood pressure reduction using ACE inhibitors or drugs of other classes, or both, frequently in combination with diuretics reduces albuminuria, delays the progression of nephropathy, postpones renal failure and improves survival in patients with diabetic nephropathy. Antihypertensive treatment for diabetic nephropathy extends life and saves money.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9534107

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  5 in total

1.  The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.

Authors:  Taco B M Monster; Wilbert M T Janssen; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 2.  Antihypertensive drugs and diabetic nephropathy.

Authors:  P S Mehler; R W Schrier
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 3.  Cost-effective strategies in the prevention of diabetic nephropathy.

Authors:  Jonathan D Rippin; Anthony H Barnett; Stephen C Bain
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Diabetic nephropathy: prescription trends in tertiary care.

Authors:  D Padmini Devi; Jennifer George
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

Review 5.  The economic impact of hypertension.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.